Atossa Therapeutics (ATOS) vs Cocrystal Pharma (COCP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Cocrystal Pharma (COCP) has outperformed Atossa Therapeutics (ATOS) over the past year, losing 12.3% versus a loss of 86.2%. Over five years, COCP leads with a -90.5% price change compared with -94.3% for ATOS. Atossa Therapeutics is the larger company by market cap ($24.3 million vs $20.6 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATOS | COCP |
|---|---|---|
| Share price | $2.44 | $1.07 |
| Market cap | $24.35M | $20.61M |
| 1-day change | +0.83% | 0.00% |
| YTD return | -72.43% | +9.18% |
| 1-year return | -86.21% | -12.30% |
| 5-year return | -94.31% | -90.51% |
| EPS (TTM) | $-4.49 | $-0.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.00 | $2.03 |
| 52-week low | $1.70 | $0.76 |
| Distance from 52-week high | -86.44% | -47.29% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +678.69% | +741.12% |
| Average volume | 63.48K | 56.73K |
| Shares outstanding | 9.98M | 19.26M |
| Employees | 16 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- COCP has outperformed ATOS by 73.9 percentage points over the past year.
About Atossa Therapeutics
ATOS stock →Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
About Cocrystal Pharma
COCP stock →Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
ATOS vs COCP FAQ
Which is bigger, Atossa Therapeutics or Cocrystal Pharma?
Atossa Therapeutics (ATOS) is larger, with a market capitalization of $24.35M compared with $20.61M for Cocrystal Pharma (COCP).
Which stock has performed better over the past year, ATOS or COCP?
COCP returned -12.30% over the past 12 months, compared with -86.21% for ATOS (price return, excluding dividends). Past performance does not predict future results.
Are Atossa Therapeutics and Cocrystal Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.